School of Pharmaceutical Sciences, Collaborative Innovation Center for Brain Science and Chongqing Key Laboratory of Natural Product Synthesis and Drug Research, Chongqing University, Chongqing, 401331, China.
College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China.
Acta Pharmacol Sin. 2021 Aug;42(8):1354-1367. doi: 10.1038/s41401-020-00541-z. Epub 2020 Oct 29.
Group I metabotropic glutamate receptors (mGlu and mGlu) are promising targets for multiple psychiatric and neurodegenerative disorders. Understanding the subtype selectivity of mGlu and mGlu allosteric sites is essential for the rational design of novel modulators with single- or dual-target mechanism of action. In this study, starting from the deposited mGlu and mGlu crystal structures, we utilized computational modeling approaches integrating docking, molecular dynamics simulation, and efficient post-trajectory analysis to reveal the subtype-selective mechanism of mGlu and mGlu to 10 diverse drug scaffolds representing known negative allosteric modulators (NAMs) in the literature. The results of modeling identified six pairs of non-conserved residues and four pairs of conserved ones as critical features to distinguish the selective NAMs binding to the corresponding receptors. In addition, nine pairs of residues are beneficial to the development of novel dual-target NAMs of group I metabotropic glutamate receptors. Furthermore, the binding modes of a reported dual-target NAM (VU0467558) in mGlu and mGlu were predicted to verify the identified residues that play key roles in the receptor selectivity and the dual-target binding. The results of this study can guide rational structure-based design of novel NAMs, and the approach can be generally applicable to characterize the features of selectivity for other G-protein-coupled receptors.
I 型代谢型谷氨酸受体(mGlu 和 mGlu)是多种精神疾病和神经退行性疾病的有希望的靶点。了解 mGlu 和 mGlu 变构位点的亚型选择性对于设计具有单一或双重作用机制的新型调节剂至关重要。在这项研究中,我们从已发表的 mGlu 和 mGlu 晶体结构出发,利用整合对接、分子动力学模拟和高效后轨迹分析的计算建模方法,揭示了 mGlu 和 mGlu 对 10 种不同药物支架的亚型选择性机制,这些药物支架代表了文献中已知的负变构调节剂(NAMs)。建模结果确定了六对非保守残基和四对保守残基作为区分相应受体选择性 NAMs 结合的关键特征。此外,有九对残基有利于开发新型 I 型代谢型谷氨酸受体的双重靶标 NAMs。此外,还预测了报告的双重靶标 NAM(VU0467558)在 mGlu 和 mGlu 中的结合模式,以验证在受体选择性和双重靶标结合中起关键作用的鉴定残基。这项研究的结果可以指导新型 NAMs 的合理基于结构的设计,并且该方法可以普遍适用于表征其他 G 蛋白偶联受体的选择性特征。